Drug

Thymidine

In clinical development

Emerging researchEarly-to-mid development

Also known as 2'-deoxy-5-methyluridine, 2'-thymidine, 5-Methyl-2?-deoxyuridine, DEOXYRIBOTHYMIDINE+10 more

2'-deoxy-5-methyluridine, 2'-thymidine, 5-Methyl-2?-deoxyuridine, DEOXYRIBOTHYMIDINE, DOXRIBTIMINE, Deoxyribosylthymine, Kygevvi, MT-1621 COMPONENT 2'-DEOXYTHYMIDINE, Thymine 2'-deoxyriboside, Thymine deoxyriboside, dThd, 1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-5-METHYLPYRIMIDINE-2,4(1H,3H)-DIONE, 1-(2-Deoxy-?-D-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione, 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-?-D-erythro-pentofuranosyl)-5-methyl-.

RxNorm1372538 ChEMBLCHEMBL52609UNIIVC2W18DGKR

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Deoxythymidine and Deoxycytidine Treatment for Thymidine Kinase 2 (TK2) Deficiency

Clinical trial2026-01-28Results expected Q4 2026 · ClinicalTrials.gov

Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity

Clinical trial2005-06-24Completed · ClinicalTrials.gov

Regulation of adult neurogenesis by excitatory input and NMDA receptor activation in the dentate gyrus.

Research1995-06-01The Journal of neuroscience : the official journal of the Society for Neuroscience

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Thymidine

Aliases & brands

2'-deoxy-5-methyluridine2'-thymidine5-Methyl-2?-deoxyuridineDEOXYRIBOTHYMIDINEDOXRIBTIMINEDeoxyribosylthymineKygevviMT-1621 COMPONENT 2'-DEOXYTHYMIDINEThymine 2'-deoxyribosideThymine deoxyribosidedThd1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-5-METHYLPYRIMIDINE-2,4(1H,3H)-DIONE1-(2-Deoxy-?-D-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-?-D-erythro-pentofuranosyl)-5-methyl-

RxNorm CUI

1372538

ChEMBL ID

CHEMBL52609

UNII

VC2W18DGKR

Clinical trials

2 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

Active studies

Completed

PHASE DISTRIBUTIONn = 2

Phase 1 / 21Phase 21

Recent completions

Trials that read out recently, adding to the completed evidence base.

Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity

CompletedPH IINational Center for Research Resources (NCRR)

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Regulation of adult neurogenesis by excitatory input and NMDA receptor activation in the dentate gyrus.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 1995 · 520 cites